At least 54 cell-aging papers appear to have used an E. coli beta-galactosidase antibody to detect mammalian SA-beta-gal

Sholto David, Holly Else (Nature News)

1. 01

   At least 54 papers list an antibody raised against E. coli beta-galactosidase for detection of mammalian SA-beta-gal

2. 02

   Affected papers span high-profile journals (Cell, Nature Aging) and lower-impact titles

3. 03

   Cross-kingdom antibody reactivity is not supported by theoretical or experimental evidence

4. 04

   Traced to a 2016 Cell paper on in vivo partial reprogramming (Izpisua Belmonte lab) listing an E. coli beta-gal antibody used on mouse liver

5. 05

   Cell states it is investigating; Springer Nature states it will assess and take editorial action if concerns are validated

6. 06

   Compounds a pre-existing dispute over whether SA-beta-gal staining reliably identifies senescent cells

7. 07

   Practical implication: senescence claims resting on SA-beta-gal alone should be treated as unverified

Study Design

Review

Sample Size

54 subjects

Study Duration

Post-publication audit; papers span 2010–2026

Methodology

Independent post-publication review of methods sections and antibody catalogue numbers across the cellular senescence literature, cross-referenced against manufacturer species-reactivity specifications; reported publicly on the For Better Science blog (21 July 2026) and covered by Nature News (21 August 2026) with responses from affected authors, journals and publishers.

Limitations

This is journalism reporting a post-publication audit, not a peer-reviewed re-analysis. It has not been established that the flagged antibody use invalidates any specific paper's conclusions; in several instances the affected experiments were ancillary, and at least one author states the error does not affect the reported findings. Journal investigations were ongoing at the time of reporting. Some manufacturers state possible cross-species reactivity, though generally without experimental confirmation.